De Kouchkovsky I, Abdul-Hay M. Acute myeloid leukemia: a comprehensive review and 2016 update. Blood Cancer J. 2016;6(7):e441.

Article  PubMed  PubMed Central  Google Scholar 

Prada-Arismendy J, Arroyave JC, Röthlisberger S. Molecular biomarkers in acute myeloid leukemia. Blood Rev. 2017;31(1):63–76.

Article  CAS  PubMed  Google Scholar 

Cancer statistics, 2024 - Siegel - 2024 - CA: A Cancer Journal for Clinicians - Wiley Online Library [Internet]. [cited 2024 Jul 25]. Available from: https://acsjournals.onlinelibrary.wiley.com/doi/https://doi.org/10.3322/caac.21820

Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: recent progress and enduring challenges. Blood Rev. 2019;36:70–87.

Article  PubMed  Google Scholar 

Haines RJ, Pendleton LC, Eichler DC. Argininosuccinate synthase: at the center of arginine metabolism. Int J Biochem Mol Biol. 2010;2(1):8–23.

Google Scholar 

Long Y, Tsai WB, Wang D, Hawke DH, Savaraj N, Feun LG, et al. Argininosuccinate synthetase 1 (ASS1) is a common metabolic marker of chemosensitivity for targeted arginine- and glutamine-starvation therapy. Cancer Lett. 2017;1(388):54–63.

Article  Google Scholar 

Hernandez CP, Morrow K, Lopez-Barcons LA, Zabaleta J, Sierra R, Velasco C, et al. Pegylated arginase I: a potential therapeutic approach in T-ALL. Blood. 2010;115(25):5214–21.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Manca A, Sini MC, Izzo F, Ascierto PA, Tatangelo F, Botti G, et al. Induction of arginosuccinate synthetase (ASS) expression affects the antiproliferative activity of arginine deiminase (ADI) in melanoma cells. Oncol Rep. 2011;25(6):1495–502.

CAS  PubMed  Google Scholar 

Miraki-Moud F, Ghazaly E, Ariza-McNaughton L, Hodby KA, Clear A, Anjos-Afonso F, et al. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Blood. 2015;125(26):4060–8.

Article  CAS  PubMed  Google Scholar 

Stone EM, Glazer ES, Chantranupong L, Cherukuri P, Breece RM, Tierney DL, et al. Replacing Mn2+ with Co2+ in human arginase i enhances cytotoxicity towards L-Arginine auxotrophic cancer cell lines. ACS Chem Biol. 2010;5(3):333–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Glazer ES, Stone EM, Zhu C, Massey KL, Hamir AN, Curley SA. Bioengineered human arginase i with enhanced activity and stability controls hepatocellular and pancreatic carcinoma xenografts. Transl Oncol. 2011;4(3):138–46.

Article  PubMed  PubMed Central  Google Scholar 

Harris JM, Chess RB. Effect of pegylation on pharmaceuticals. Nat Rev Drug Discov. 2003;2(3):214–21.

Article  CAS  PubMed  Google Scholar 

Tanios R, Bekdash A, Kassab E, Stone E, Georgiou G, Frankel AE, et al. Human recombinant arginase I(Co)-PEG5000 [HuArgI(Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human acute myeloid leukemia cells. Leuk Res. 2013;37(11):1565–71.

Article  CAS  PubMed  Google Scholar 

Kuo MT, Savaraj N, Feun LG. Targeted cellular metabolism for cancer chemotherapy with recombinant arginine-degrading enzymes. Oncotarget. 2010;1(4):246–51.

Article  PubMed  PubMed Central  Google Scholar 

Khalil N, Abi-Habib RJ. [HuArgI (co)-PEG5000]-induced arginine deprivation leads to autophagy dependent cell death in pancreatic cancer cells. Invest New Drugs. 2020;38(5):1236–46.

Article  CAS  PubMed  Google Scholar 

Al-Koussa H, Al-Haddad M, Abi-Habib R, El-Sibai M. Human Recombinant Arginase I [HuArgI (Co)-PEG5000]-induced arginine depletion inhibits colorectal cancer cell migration and invasion. Int J Mol Sci. 2019;20(23):6018.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Swayden M, Bekdash A, Fakhoury I, El-Atat O, Borjac-Natour J, El-Sibai M, et al. Activation of autophagy following [HuArgI (Co)-PEG5000]-induced arginine deprivation mediates cell death in colon cancer cells. Hum Cell. 2021;34(1):152–64.

Article  CAS  PubMed  Google Scholar 

Cheng PNM, Lam TL, Lam WM, Tsui SM, Cheng AWM, Lo WH, et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67(1):309–17.

Article  CAS  PubMed  Google Scholar 

Nasreddine G, El-Sibai M, Abi-Habib RJ. Cytotoxicity of [HuArgI (co)-PEG5000]-induced arginine deprivation to ovarian Cancer cells is autophagy dependent. Invest New Drugs. 2020;38(1):10–9.

Article  CAS  PubMed  Google Scholar 

Leung SL, Ho MK, Lam YM, Chow HY, So YH, Leung YC. PEGylated recombinant human arginase as a drug for breast cancer. Hong Kong Med J Xianggang Yi Xue Za Zhi. 2019;25(Suppl 9(6)):28–31.

PubMed  Google Scholar 

Wang Z, Shi X, Li Y, Fan J, Zeng X, Xian Z, et al. Blocking autophagy enhanced cytotoxicity induced by recombinant human arginase in triple-negative breast cancer cells. Cell Death Dis. 2014;5(12):e1563–e1563.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khoury O, Ghazale N, Stone E, El-Sibai M, Frankel AE, Abi-Habib RJ. Human recombinant arginase I (Co)-PEG5000 [HuArgI (Co)-PEG5000]-induced arginine depletion is selectively cytotoxic to human glioblastoma cells. J Neurooncol. 2015;122(1):75–85.

Article  CAS  PubMed  Google Scholar 

Yoon CY, Shim YJ, Kim EH, Lee JH, Won NH, Kim JH, et al. Renal cell carcinoma does not express argininosuccinate synthetase and is highly sensitive to arginine deprivation via arginine deiminase. Int J Cancer. 2007;120(4):897–905.

Article  CAS  PubMed  Google Scholar 

Hsueh EC, Knebel SM, Lo WH, Leung YC, Cheng PNM, Hsueh CT. Deprivation of arginine by recombinant human arginase in prostate cancer cells. J Hematol OncolJ Hematol Oncol. 2012;30(5):17.

Article  Google Scholar 

Dinh V, You M, Savaraj N, Wu C, Kuo MT, Wangpaichitr M, et al. Determining argininosuccinate synthetase (ASS) expression in patients with melanoma treated with arginine depleting therapy. J Clin Oncol. 2011;29(15):10627–10627.

Article  Google Scholar 

Results Submitted | A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS | ClinicalTrials.gov [Internet]. [cited 2024 Aug 9]. Available from: https://clinicaltrials.gov/study/NCT02732184?tab=results

Mussai F, Egan S, Higginbotham-Jones J, Perry T, Beggs A, Odintsova E, et al. Arginine dependence of acute myeloid leukemia blast proliferation: a novel therapeutic target. Blood. 2015;125(15):2386–96.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cai Y, Chow JPH, Leung YO, Lu X, Yuen CH, Lee WL, et al. NEI-01-Induced arginine deprivation has potent activity against acute myeloid leukemia cells both in vitro and in vivo. Mol Cancer Ther. 2021;20(11):2218–27.

Article  CAS  PubMed  Google Scholar 

Tsai HJ, Jiang SS, Hung WC, Borthakur G, Lin SF, Pemmaraju N, et al. A Phase II study of arginine deiminase (ADI-PEG20) in relapsed/refractory or poor-risk acute myeloid leukemia patients. Sci Rep. 2017;7(1):11253.

Article  PubMed  PubMed Central  Google Scholar 

Tsai HJ, Hsiao HH, Hsu YT, Liu YC, Kao HW, Liu TC, et al. Phase I study of ADI-PEG20 plus low-dose cytarabine for the treatment of Acute Myeloid Leukemia. Cancer Med. 2021;10(9):2946–55.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Changou CA, Chen YR, Xing L, Yen Y, Chuang FYS, Cheng RH, et al. Arginine starvation-associated atypical cellular death involves mitochondrial dysfunction, nuclear DNA leakage, and chromatin autophagy. Proc Natl Acad Sci U S A. 2014;111(39):14147–52.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Syed N, Langer J, Janczar K, Singh P, Lo Nigro C, Lattanzio L, et al. Epigenetic status of argininosuccinate synthetase and argininosuccinate lyase modulates autophagy and cell death in Glioblastoma. Cell Death Dis. 2013;4(1):e458–e458.

Article  CAS  PubMed  PubMed Central  Google Scholar